Physician profile
Ryan Russell
NPI 1841751187
$2,194.81
in general payments reported to CMS, 2019-2025
21 companies · $649 in 2025
The $649 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.35 · 2023: $735 · 2024: $793 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,021.12 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $317.61 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $227.62 | 2023 | |
| Lilly USA, LLC | $90.43 | 2023-2025 | Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals LP | $78.72 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.80 | 2025 | Caplyta |
| Pfizer INC. | $58.96 | 2023-2025 | |
| Edwards Lifesciences Corporation | $39.77 | 2024 | Sapien 3 Ultra Resilia |
| Otsuka America Pharmaceutical, INC. | $36.81 | 2025 | Rexulti |
| Harmony Biosciences LLC | $32.39 | 2024 | |
| Amgen INC. | $29.55 | 2023-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $27.95 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Mallinckrodt Hospital Products INC. | $27.52 | 2025 | Acthar |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.58 | 2024 | |
| Mylan Specialty L.P. | $22.53 | 2024 | Yupelri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $21.67 | 2025 | |
| Radius Health, INC. | $18.40 | 2025 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $16.14 | 2023 | Gattex |
| Axsome Therapeutics, INC. | $15.24 | 2024 | Auvelity |
| Alkermes, INC. | $14.54 | 2025 | Lybalvi |
| Neurelis, INC. | $14.46 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.